Skip to content

Macular Thickness and Visual Acuity in Diabetic Hypertensive Patients

Macular Thickness and Visual Acuity in Diabetic Hypertensive Patients in Sohag City

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05209971
Enrollment
100
Registered
2022-01-27
Start date
2022-01-31
Completion date
2022-12-31
Last updated
2022-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Edema

Keywords

Macular thickness and visual acuity

Brief summary

In this study, measurements of central macular thickness using optical coherence tomography along with examination of visual acuity by Snellen's chart in diabetic hypertensive patients will be done .

Detailed description

correlate relationship between optical coherence tomography changes and visual acuity in patients with type 2 diabetes and hypertension

Interventions

None listed

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Type 2 diabetic patients with hypertension .

Exclusion criteria

* Patients with type 1 diabetes mellitus . * Ocular disease ( such as high myopia , glaucoma ) . * Patients with opacities in the media ( corneal opacities , dense cataract , vitreous hemorrhage ) . * Systemic medication (Tamoxifen , Chloroquine , Canthaxanthine ) to avoid its effect on macular thickness . * Central visual field defect that prevents fixation on OCT . * Intraocular inflammation such as anterior or posterior uveitis . * Refractive error greater than 6 diopter .

Design outcomes

Primary

MeasureTime frameDescription
macular thickness in diabetic hypertensive patientsJune 2022measurement of central macular thickness by optical coherence tomography

Contacts

Primary ContactGamal Abdelateef, professor
raghdaabdelraheem89@gmail.com01001244421
Backup ContactAlahmady Hamad, professor
raghdelaysh@gmail.com01111102698

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026